Cloxyquin

Cloxyquin

SCHEMBL4977328

Oc1ccc(Cl)c2cccnc12.[Mn]

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.96
HSP90AA1 P07900 6/20 0.96
LMNA P02545 5/20 0.96
MAPT P10636 5/20 0.96
METAP2 P50579 3/20 0.96
METAP1 P53582 2/20 0.96
BRD4 O60885 2/20 0.96
L3MBTL1 Q9Y468 5/20 0.59
HTT P42858 5/20 0.59
SLC6A2 P23975 3/20 0.59
IDO1 P14902 2/20 0.59
MPI P34949 1/20 0.59
HSP90AB1 P08238 1/20 0.59
PSMB5 P28074 1/20 0.59
SMN1; SMN2 Q16637 4/20 0.58
NPC1 O15118 4/20 0.58
RAB9A P51151 4/20 0.58
ALDH1A1 P00352 4/20 0.58
TDP1 Q9NUW8 4/20 0.58
MEN1 O00255 3/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cloxyquin SCHEMBL29381298 0.98 KDM4E (1.00) KDM4EHSP90AA1LMNAMAPTMETAP2
Cloxyquin SCHEMBL115838 0.98 KDM4E (1.00) KDM4EHSP90AA1LMNAMAPTMETAP2
Cloxyquin SCHEMBL4291941 0.96 KDM4E (0.96) KDM4EHSP90AA1LMNAMAPTMETAP2
Cloxyquin SCHEMBL4292402 0.96 KDM4E (0.96) KDM4EHSP90AA1LMNAMAPTMETAP2
Cloxyquin SCHEMBL4776305 0.96 KDM4E (0.96) KDM4EHSP90AA1LMNAMAPTMETAP2
Cloxyquin SCHEMBL4977294 0.96 KDM4E (0.96) KDM4EHSP90AA1LMNAMAPTMETAP2
Cloxyquin SCHEMBL360578 0.96 KDM4E (0.96) KDM4EHSP90AA1LMNAMAPTMETAP2
Cloxyquin SCHEMBL4978867 0.96 KDM4E (0.96) KDM4EHSP90AA1LMNAMAPTMETAP2
Cloxyquin SCHEMBL4302919 0.96 KDM4E (0.96) KDM4EHSP90AA1LMNAMAPTMETAP2
Cloxyquin SCHEMBL317736 0.96 KDM4E (0.96) KDM4EHSP90AA1LMNAMAPTMETAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112438266-A Application of 8-hydroxyquinoline manganese, magnesium and nickel complex in preparation of agricultural bactericide 兰州大学 2021-03-05 CN disclosed
US-20080063599-A1 Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils BARNATRON, S.A. (ES) 2008-03-13 US disclosed
EP-1563852-B1 COMPOUNDS WHICH CAN BE USED TO DIAGNOSE AND MONITOR DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID PROTEIN FIBRILS CETIR CT MEDIC S A (ES) 2007-11-21 EP disclosed
EP-1563852-A1 COMPOUNDS WHICH CAN BE USED TO DIAGNOSE AND MONITOR DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID PROTEIN FIBRILS Cetir Centre Medic, S.A. (ES) 2005-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080063599-A1 Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils APP, TTR, IAPP KDM4E 4615/4885HSP90AA1 1019/4885LMNA 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.